WO2023128984A1 - Cox-1, cox-2 and lox enzyme inhibiting effects of standardized extracts of crataegus monoygna fruits and leaves with flowerleaves with flowers - Google Patents
Cox-1, cox-2 and lox enzyme inhibiting effects of standardized extracts of crataegus monoygna fruits and leaves with flowerleaves with flowers Download PDFInfo
- Publication number
- WO2023128984A1 WO2023128984A1 PCT/TR2022/051057 TR2022051057W WO2023128984A1 WO 2023128984 A1 WO2023128984 A1 WO 2023128984A1 TR 2022051057 W TR2022051057 W TR 2022051057W WO 2023128984 A1 WO2023128984 A1 WO 2023128984A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crataegus
- monoygna
- cox
- leaves
- hyperoside
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 37
- 235000014493 Crataegus Nutrition 0.000 title claims abstract description 31
- 241001092040 Crataegus Species 0.000 title claims abstract description 31
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 title description 3
- 108090000790 Enzymes Proteins 0.000 title description 3
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 101150071146 COX2 gene Proteins 0.000 title 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 title 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 title 1
- 101150062589 PTGS1 gene Proteins 0.000 title 1
- 101150000187 PTGS2 gene Proteins 0.000 title 1
- 101150070593 lox gene Proteins 0.000 title 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 40
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 29
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 29
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims abstract description 28
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 28
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims abstract description 28
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims abstract description 28
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims abstract description 28
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 claims abstract description 21
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 claims abstract description 21
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 claims abstract description 21
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 20
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 20
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- 102100020720 Calcium channel flower homolog Human genes 0.000 description 14
- 101000932468 Homo sapiens Calcium channel flower homolog Proteins 0.000 description 14
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 6
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000000059 Vitex cofassus Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- -1 sachets Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
Definitions
- the present invention is related to standardized extracts of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as an antiinflammatory agent.
- Inflammatory disorders are quite common. Treatment of inflammations occurring for different reasons in different parts of the body is attempted to be provided with various conventional drugs. However, although the treatment with these agents is sometimes insufficient, the discovery of new and natural anti-inflammatory agents is of great importance.
- the inventors aim to develop anti-inflammatory agents which are obtained from herbal or natural sources and which can be standardized in terms of the amount of pharmaceutically active substance contained in the same.
- the present invention is related to standardized extracts of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as an antiinflammatory agent.
- patients are provided with a natural anti-inflammatory agent with a standardized extract of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as the anti-inflammatory agent according to the invention.
- the present invention is related to a standardized extract of Crataegus monoygna fruits and/or leaves with flower over hyperoside and caffeic acid or vitexin for use as an anti-inflammatory agent.
- a preferred embodiment of the present invention is related to the extract of Crataegus monoygna fruits standardized on caffeic acid and hyperoside for use as an anti-inflammatory agent.
- Another embodiment of the invention is related to the standardized extract of Crataegus monoygna fruits containing at least 0,010%, preferably 0,01-0,1% caffeic acid, at least 0,01%, preferably 0,01-0,1% hyperoside, for use as an anti-inflammatory agent.
- a preferred embodiment of the invention is related to the extract of Crataegus monoygna leaves with flower standardized on vitexin and hyperoside for use as an anti-inflammatory agent.
- Another embodiment of the invention is related to the standardized extract of Crataegus monoygna leaves with flower containing at least 1%, preferably 1-5% vitexin, and at least 1%, preferably 1-5% hyperoside for use as an anti-inflammatory agent.
- anti-inflammatory agent used herein also includes agents that act as inhibitors of COX-1 and/or COX-2 and/or LOX.
- the amount of % vitexin or % hyperoside or % caffeic acid mentioned within the scope of the invention is determined with any analysis method used for the determination of hyperoside and caffeic acid or vitex in the extracts of Crataegus monoygna leaves with flower and/or Crataegus monoygna fruits, such as HPLC and/or HPTLC device analyzes.
- the % ratio mentioned within the scope of this invention is relative and expresses the amount of vitexin or hyperoside compared to the total amount of substance in the extracted sample of Crataegus monoygna leaves with flower analyzed. For example, if the entire peak area obtained in HPLC analysis of a sample of extract of Crataegus monoygna leaves with flower is expressed by 100, then the area of the peak corresponding to hyperoside in a sample of extract of leaves with flower of Crataegus monoygna according to the invention should be at least 1. The same applies to the vitexin substance in this extract and the caffeic acid and hyperoside found in the extracts of Crataegus monoygna fruits.
- the invention is related to the pharmaceutical compositions comprising a standardized extract of Crataegus monoygna fruits and/or leaves with flower suitable for use as an anti-inflammatory agent on hyperoside and caffeic acid or vitexin.
- a preferred embodiment of the invention relates to the pharmaceutical compositions suitable for use as an anti-inflammatory agent, comprising the standardized extract of Crataegus monoygna leaves with flower as the active ingredient, containing at least 1%, preferably 1-5% vitexin, and at least 1%, preferably 1-5% hyperoside.
- a preferred embodiment of the invention relates to the pharmaceutical compositions comprising standardized extract which contains at least 0,010%, preferably 0,01-0,1% caffeic acid, and at least 0,01%, preferably 0,01-0,1% hyperoside of Crataegus monoygna fruits as the active ingredient, suitable for use as an anti-inflammatory agent.
- Another feature of the invention is the use of another anti-inflammatory agent in addition to these active ingredients mentioned in pharmaceutical compositions
- pharmaceutical compositions comprising the standardized extract of Crataegus monoygna leaves with flower containing at least 1%, preferably 1-5% vitexin and at least 1%, preferably 1-5% hyperoside, or Crataegus monoygna fruits containing at least 0,010%, preferably 0,01-0,1% caffeic acid, and at least 0,01%, preferably 0,01-0,1% hyperoside as an active ingredient.
- the said additional anti-inflammatory agent may be ibuprofen or diclofenac.
- the combinations according to the invention can be formulated in the same dosage form or different dosage forms.
- the said formulations can be used at different times or simultaneously or sequentially.
- compositions according to the invention may be formulated in a dosage form suitable for oral or topical use.
- Oral formulations may be in any of the forms of tablets, capsules, extended-release capsules, delayed-release capsules, syrups, emulsions, suspensions, coated tablets, layered tablets, orally dispersible tablets, effervescent tablets, sachets, sublingual tablets.
- Topical formulations may be in any of the forms of ointment, cream, gel, hydrogel, or lotion.
- agents of natural origin suitable for use as anti-inflammatory agents have been developed.
- the invention concerns both end users in the health sector and medication developers. Examples
- Example 1 IC50 values of the Crataegus monoygna fruit extract according to the invention for COX-1 and COX-2 inhibition and comparison with known anti-inflammatory agents
- the Crataegus monoygna fruit extract used in the study given below contains 0,012% caffeic acid and 0,04% hyperoside.
- Example 2 IC50 values of the Crataegus monoygna floral leaf extract according to the invention for COX-1 and COX-2 inhibition and comparison with known anti-inflammatory agents
- the Crataegus monoygna floral leaf extract used in the study given below contains 1.1% vitexin and 2.8% hyperoside.
- vitexin and/or hyperoside is a natural extract, they have anti-inflammatory effects that are better or significantly better than long-time commercially used anti-inflammatory agents.
- the said anti-inflammatory effect is demonstrated through COX-1 and/or COX-2 inhibition.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is related to standardized extracts of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as an anti-inflammatory agent.
Description
COX-1, COX-2 AND LOX ENZYME INHIBITING EFFECTS OF STANDARDIZED EXTRACTS OF CRATAEGUS MONO YGNA FRUITS AND LEAVES WITH FLOWERLEAVES WITH FLOWERS
Technical Field
The present invention is related to standardized extracts of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as an antiinflammatory agent.
State of the Art
Inflammatory disorders are quite common. Treatment of inflammations occurring for different reasons in different parts of the body is attempted to be provided with various conventional drugs. However, although the treatment with these agents is sometimes insufficient, the discovery of new and natural anti-inflammatory agents is of great importance.
One of the most common problems in the commercial use of therapeutic agents of natural origin is that the amount of pharmaceutically active substances in the extracts obtained from natural products is not fixed. This change in amount, which may vary according to the region where the plant was collected or the period in which it was collected, prevents the development of formulations that can be replicated and standardized by using herbal extracts.
Considering the state of the art, it is seen that there is a need for anti-inflammatory agents that can be standardized in terms of the amount of the pharmaceutically active substance obtained from herbal or natural sources.
The object of the Invention
The inventors aim to develop anti-inflammatory agents which are obtained from herbal or natural sources and which can be standardized in terms of the amount of pharmaceutically active substance contained in the same.
Brief Description of the Invention
The present invention is related to standardized extracts of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as an antiinflammatory agent.
Since standardized extracts are used in the invention for their vitexin, caffeic acid, and/or hyperoside content, the results of the study can be repeated and they are debatable.
In addition, since there are not many natural agents that selectively inhibit COX and LOX enzymes, patients are provided with a natural anti-inflammatory agent with a standardized extract of Crataegus monoygna fruits and/or leaves with flower over caffeic acid, vitexin, and/or hyperoside for use as the anti-inflammatory agent according to the invention.
Detailed Description of the Invention
The present invention is related to a standardized extract of Crataegus monoygna fruits and/or leaves with flower over hyperoside and caffeic acid or vitexin for use as an anti-inflammatory agent.
A preferred embodiment of the present invention is related to the extract of Crataegus monoygna fruits standardized on caffeic acid and hyperoside for use as an anti-inflammatory agent.
Another embodiment of the invention is related to the standardized extract of Crataegus monoygna fruits containing at least 0,010%, preferably 0,01-0,1% caffeic acid, at least 0,01%, preferably 0,01-0,1% hyperoside, for use as an anti-inflammatory agent.
A preferred embodiment of the invention is related to the extract of Crataegus monoygna leaves with flower standardized on vitexin and hyperoside for use as an anti-inflammatory agent.
Another embodiment of the invention is related to the standardized extract of Crataegus
monoygna leaves with flower containing at least 1%, preferably 1-5% vitexin, and at least 1%, preferably 1-5% hyperoside for use as an anti-inflammatory agent.
The term anti-inflammatory agent used herein also includes agents that act as inhibitors of COX-1 and/or COX-2 and/or LOX.
In the source titled Turkish Pharmacopoeia-II monographs (Turk Farmakopesi-II monograflar) (European Pharmacopoeia adaptation) - 2016 (T.R. Ministry of Health, Turkey Pharmaceuticals and Medical Devices Agency, 1. Edition, 2016), the amount of % vitexin or % hyperoside or % caffeic acid mentioned within the scope of the invention is determined with any analysis method used for the determination of hyperoside and caffeic acid or vitex in the extracts of Crataegus monoygna leaves with flower and/or Crataegus monoygna fruits, such as HPLC and/or HPTLC device analyzes.
The % ratio mentioned within the scope of this invention is relative and expresses the amount of vitexin or hyperoside compared to the total amount of substance in the extracted sample of Crataegus monoygna leaves with flower analyzed. For example, if the entire peak area obtained in HPLC analysis of a sample of extract of Crataegus monoygna leaves with flower is expressed by 100, then the area of the peak corresponding to hyperoside in a sample of extract of leaves with flower of Crataegus monoygna according to the invention should be at least 1. The same applies to the vitexin substance in this extract and the caffeic acid and hyperoside found in the extracts of Crataegus monoygna fruits.
In another aspect, the invention is related to the pharmaceutical compositions comprising a standardized extract of Crataegus monoygna fruits and/or leaves with flower suitable for use as an anti-inflammatory agent on hyperoside and caffeic acid or vitexin.
A preferred embodiment of the invention relates to the pharmaceutical compositions suitable for use as an anti-inflammatory agent, comprising the standardized extract of Crataegus monoygna leaves with flower as the active ingredient, containing at least 1%, preferably 1-5% vitexin, and at least 1%, preferably 1-5% hyperoside.
A preferred embodiment of the invention relates to the pharmaceutical compositions comprising standardized extract which contains at least 0,010%, preferably 0,01-0,1% caffeic
acid, and at least 0,01%, preferably 0,01-0,1% hyperoside of Crataegus monoygna fruits as the active ingredient, suitable for use as an anti-inflammatory agent.
Another feature of the invention is the use of another anti-inflammatory agent in addition to these active ingredients mentioned in pharmaceutical compositions comprising the standardized extract of Crataegus monoygna leaves with flower containing at least 1%, preferably 1-5% vitexin and at least 1%, preferably 1-5% hyperoside, or Crataegus monoygna fruits containing at least 0,010%, preferably 0,01-0,1% caffeic acid, and at least 0,01%, preferably 0,01-0,1% hyperoside as an active ingredient.
In one embodiment of the invention, the said additional anti-inflammatory agent may be ibuprofen or diclofenac.
The combinations according to the invention can be formulated in the same dosage form or different dosage forms.
In case the combination formulations according to the invention are formulated in different dosage forms, the said formulations can be used at different times or simultaneously or sequentially.
The formulations according to the invention may be formulated in a dosage form suitable for oral or topical use. Oral formulations may be in any of the forms of tablets, capsules, extended-release capsules, delayed-release capsules, syrups, emulsions, suspensions, coated tablets, layered tablets, orally dispersible tablets, effervescent tablets, sachets, sublingual tablets. Topical formulations may be in any of the forms of ointment, cream, gel, hydrogel, or lotion.
Industrial Applicability
Thanks to the invention, agents of natural origin suitable for use as anti-inflammatory agents have been developed.
In this respect, the invention concerns both end users in the health sector and medication developers.
Examples
Example 1: IC50 values of the Crataegus monoygna fruit extract according to the invention for COX-1 and COX-2 inhibition and comparison with known anti-inflammatory agents
The Crataegus monoygna fruit extract used in the study given below contains 0,012% caffeic acid and 0,04% hyperoside.
Example 2: IC50 values of the Crataegus monoygna floral leaf extract according to the invention for COX-1 and COX-2 inhibition and comparison with known anti-inflammatory agents The Crataegus monoygna floral leaf extract used in the study given below contains 1.1% vitexin and 2.8% hyperoside.
When the results in both Example 1 and Example 2 are evaluated, it is seen that even though the standardized extract of Crataegus monoygna fruits and/or leaves with flower according to the invention over caffeic acid, vitexin and/or hyperoside is a natural extract, they have anti-inflammatory effects that are better or significantly better than long-time commercially used anti-inflammatory agents. The said anti-inflammatory effect is demonstrated through COX-1 and/or COX-2 inhibition. The fact that better COX-1 and/or COX-2 inhibition compared to ibuprofen and diclofenac active ingredients, which are anti-inflammatory agents that have been used frequently in the pharmaceutical market for many years, reveals that these naturally sourced standardized extracts can be important anti-inflammatory agents. This shows that the formulations according to the invention exceed the state of the art.
Claims
CLAIMS The standardized extract of Crataegus monoygna fruits and/or leaves with flower over hyperoside and caffeic acid or vitexin for use as an anti-inflammatory agent. An extract according to Claim 1, wherein it is a standardized extract of Crataegus monoygna fruits over caffeic acid and vitexin. An extract according to Claim 2, wherein it comprises at least 0,010%, preferably 0,01-0,1% caffeic acid and at least 0,01%, preferably 0,01-0,1% hyperoside. An extract according to Claim 1, wherein it is a standardized extract of Crataegus monoygna leaves with flower over vitexin and hyperoside. An extract according to Claim 4, wherein it comprises at least 1%, preferably 1-5% vitexin, and at least 1%, preferably 1-5% hyperoside. Pharmaceutical compositions containing a standardized extract of Crataegus monoygna fruits and/or leaves with flower over hyperoside and caffeic acid or vitexin suitable for use as an anti-inflammatory agent. A pharmaceutical composition according to Claim 6, additionally comprising another anti-inflammatory agent. A pharmaceutical composition according to Claim 7, wherein the additional antiinflammatory agent is diclofenac and ibuprofen. A pharmaceutical composition according to any one of the Claims 6-8, wherein it is formulated in a dosage form suitable for oral or topical use.
7
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021021372 | 2021-12-28 | ||
| TR2021/021372 TR2021021372A1 (en) | 2021-12-28 | INHIBITORY EFFECTS OF STANDARDIZED EXTRACTS OF CRATAEGUS MONOYGNA FRUITS AND FLOWERING LEAVES ON COX-1, COX-2 AND LOX ENZYMES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023128984A1 true WO2023128984A1 (en) | 2023-07-06 |
Family
ID=87000140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2022/051057 WO2023128984A1 (en) | 2021-12-28 | 2022-09-29 | Cox-1, cox-2 and lox enzyme inhibiting effects of standardized extracts of crataegus monoygna fruits and leaves with flowerleaves with flowers |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023128984A1 (en) |
-
2022
- 2022-09-29 WO PCT/TR2022/051057 patent/WO2023128984A1/en unknown
Non-Patent Citations (3)
| Title |
|---|
| BAHORUN THEESHAN, AUMJAUD ESHA, RAMPHUL HEMLATA, RYCHA MAHESHWAREE, LUXIMON-RAMMA AMITABYE, TROTIN FRANCIS, ARUOMA OKEZIE I.: "Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts", NAHRUNG - FOOD, VCH VERLAGSGESELLSCHAFT, WEINHEIM., DE, vol. 47, no. 3, 1 June 2003 (2003-06-01), DE , pages 191 - 198, XP093078315, ISSN: 0027-769X, DOI: 10.1002/food.200390045 * |
| ŠAVIKIN KATARINA P., KRSTIĆ-MILOŠEVIĆ DIJANA B., MENKOVIĆ NEBOJŠA R., BEARA IVANA N., MRKONJIĆ ZORICA O., PLJEVLJAKUŠIĆ DEJAN S.: "Crataegus orientalis Leaves and Berries: Phenolic Profiles, Antioxidant and Anti-inflammatory Activity", NATURAL PRODUCT COMMUNICATIONS, NATURAL PRODUCT INC., US, vol. 12, no. 2, 1 February 2017 (2017-02-01), US , pages 1934578X1701200, XP093078313, ISSN: 1934-578X, DOI: 10.1177/1934578X1701200204 * |
| TADIĆ VANJA M., DOBRIĆ SILVA, MARKOVIĆ GORAN M., ÐORĐEVIĆ SOFIJA M., ARSIĆ IVANA A., MENKOVIĆ NEBOJŠA R., STEVIĆ TANJA: "Anti-inflammatory, Gastroprotective, Free-Radical-Scavenging, and Antimicrobial Activities of Hawthorn Berries Ethanol Extract", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 56, no. 17, 10 September 2008 (2008-09-10), US , pages 7700 - 7709, XP093078312, ISSN: 0021-8561, DOI: 10.1021/jf801668c * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sosa et al. | Screening of the topical anti-inflammatory activity of some Central American plants | |
| Momin et al. | Coriandrum sativum-review of advances in phytopharmacology | |
| Powanda et al. | Celery seed and related extracts with antiarthritic, antiulcer, and antimicrobial activities | |
| Megersa et al. | The use of medicinal plants for the treatment of toothache in Ethiopia | |
| Dzoyem et al. | Antimycobacterial activity against different pathogens and selectivity index of fourteen medicinal plants used in southern Africa to treat tuberculosis and respiratory ailments | |
| EP2221052A2 (en) | Compositions that treat or inhibit pathological conditions associated with inflammatory response | |
| Singh et al. | Ethnopharmacological, phytochemical and clinical studies on Fenugreek (Trigonella foenum-graecum L.) | |
| Mujahid et al. | An insight of pharmacognostic and phytopharmacology study of Adenanthera pavonina | |
| Schaffer et al. | Harpagophytum procumbens prevents oxidative stress and loss of cell viability in vitro | |
| EP1844786B1 (en) | Extracts of Curcuma longa and their cosmetic and dermatological uses | |
| Delfani et al. | Systematic review for phytotherapy in Streptococcus Mutans | |
| Kumari et al. | Promising essential oils/plant extracts in the prevention and treatment of dandruff pathogenesis | |
| Aleem | Anti-inflammatory and anti-microbial potential of Plumbago zeylanica L.: a review | |
| Almekhlafi et al. | Antimicrobial activity of Yemeni myrrh mouthwash | |
| Kokou et al. | Effect of Aframomum melegueta on carbon tetrachloride induced liver injury | |
| WO2023128984A1 (en) | Cox-1, cox-2 and lox enzyme inhibiting effects of standardized extracts of crataegus monoygna fruits and leaves with flowerleaves with flowers | |
| Alabdallat | In-vivo antioxidant effects of the orally administered paracetamol, aqueous extracts of saliva triloba, and origanum syriacum | |
| EA034493B1 (en) | Mouth freshener | |
| WO2023128999A1 (en) | Natural compounds with anti-inflammatory effect | |
| WO2023128988A1 (en) | Inhibitory effects of standardized extracts of malva sylvestris flowers on cox-1, cox-2 and lox enzymes | |
| WO2023128989A1 (en) | Inhibitory effects of standardized extracts of rosmarinus officinalis leaves on cox-1, cox-2 and lox enzymes | |
| WO2023128987A1 (en) | Inhibitory effects of standardized extracts of allium sativum l. onions on cox-1, cox-2 and lox enzymes | |
| WO2023128990A1 (en) | Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes | |
| WO2023128991A1 (en) | Inhibitory effects of standardized extracts of taraxacum officinale aerial parts on cox-1, cox-2 and lox enzymes | |
| HU221593B (en) | Process for preparation of plant-based pharmaceutical compositions for enhancing or modifying the tone of smooth-muscle organs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22916987 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |